

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).



Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>New Leaf Venture Management III, L.L.C.</u>  (Last) (First) (Middle) <u>C/O NEW LEAF VENTURES</u> <u>7 TIMES SQUARE, SUITE 3502</u>  (Street) <u>NEW YORK NY 10036</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Deciphera Pharmaceuticals, Inc. [ DCPH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/02/2017</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/02/2017		C		839,110	A	(1)	839,110	I	See Footnote(2)(3)
Common Stock	10/02/2017		C		1,118,722	A	(1)	1,957,832	I	See Footnote(2)(3)
Common Stock	10/02/2017		C		279,703	A	(1)	279,703	I	See Footnote(4)(5)
Common Stock	10/02/2017		C		1,118,722	A	(1)	1,398,425	I	See Footnote(4)(5)
Common Stock	10/02/2017		C		372,883	A	(1)	1,771,308	I	See Footnote(4)(5)
Common Stock	10/02/2017		P		375,000	A	\$17	2,146,308	I	See Footnote(4)(5)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B-1 Preferred Stock	(1)	10/02/2017		C		148,515		(1)	(1)	Common Stock	839,110	\$0.00	0	I	See Footnote(2)(3)
Series B-2 Preferred Stock	(1)	10/02/2017		C		198,004		(1)	(1)	Common Stock	1,118,722	\$0.00	0	I	See Footnote(2)(3)
Series B-1 Preferred Stock	(1)	10/02/2017		C		49,505		(1)	(1)	Common Stock	279,703	\$0.00	0	I	See Footnote(4)(5)
Series B-2 Preferred Stock	(1)	10/02/2017		C		198,004		(1)	(1)	Common Stock	1,118,722	\$0.00	0	I	See Footnote(4)(5)
Series C Preferred Stock	(1)	10/02/2017		C		65,997		(1)	(1)	Common Stock	372,883	\$0.00	0	I	See Footnote(4)(5)

1. Name and Address of Reporting Person\*  
New Leaf Venture Management III, L.L.C.  
  
 (Last) (First) (Middle)  
C/O NEW LEAF VENTURES  
7 TIMES SQUARE, SUITE 3502  
  
 (Street)  
NEW YORK NY 10036

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">New Leaf Ventures III, L.P.</a>		
(Last)	(First)	(Middle)
C/O NEW LEAF VENTURES		
7 TIMES SQUARE, SUITE 3502		
(Street)		
NEW YORK	NY	10036
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">New Leaf Biopharma Opportunities I, L.P.</a>		
(Last)	(First)	(Middle)
C/O NEW LEAF VENTURES		
7 TIMES SQUARE, SUITE 3502		
(Street)		
NEW YORK	NY	10036
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">New Leaf Venture Associates III, L.P.</a>		
(Last)	(First)	(Middle)
C/O NEW LEAF VENTURES		
7 TIMES SQUARE, SUITE 3502		
(Street)		
NEW YORK	NY	10036
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">New Leaf BPO Associates I, L.P.</a>		
(Last)	(First)	(Middle)
C/O NEW LEAF VENTURES		
7 TIMES SQUARE, SUITE 3502		
(Street)		
NEW YORK	NY	10036
(City)	(State)	(Zip)

**Explanation of Responses:**

- Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer.
- The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- (Continuation from footnote 2) Each of Liam Ratcliffe, a member of the Issuer's board of directors, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- (Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

**Remarks:**

[/s/ Craig Slutzkin, attorney-in-fact for New Leaf Ventures III, L.P.](#) [10/02/2017](#)

[/s/ Craig Slutzkin, attorney-in-fact for New Leaf Biopharma Opportunities I, L.P.](#) [10/02/2017](#)

[/s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Associates III, L.P.](#) [10/02/2017](#)

[/s/ Craig Slutzkin, attorney-in-fact for New Leaf BPO](#) [10/02/2017](#)

Associates I, L.P.

/s/ Craig Slutzkin, attorney-in-  
fact for New Leaf Venture  
Management III, L.L.C.

10/02/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**